Exon and intron variants in the human tryptophan 2,3-dioxygenase gene: Potential association with Tourette syndrome substance abuse and other disorders

David E. Comings, Radhika Gade, Donn Muhleman, Connie Chiu, Shijuan Wu, Michael To, Matthew Spence, George Dietz, Emily Winn-Deen, Richard J. Rosenthal, Henry R. Lesieur, Loreen Rugle, Jeffrey Sverd, Linda Ferry, James Patrick Johnson, James P. MacMurray

Research output: Contribution to journalArticlepeer-review

Abstract

Defects in serotonin metabolism, and abnormalities in both brood serotonin and tryptophan levels, have been reported in many psychiatric disorders. Tryptophan 2,3-dioxygenase (TDO2) is the rate limiting enzyme for the breakdown of tryptophan to N-formyl kenurenine. Functional variants of this gene could account for the observed simultaneous increases or decreases of both serotonin and tryptophan in various disorders. We have identified four different polymorphisms of the human TDO2 gene. Association studies show a significant association of one or more of these polymorphisms and Tourette syndrome (TS), attention deficit hyperactivity disorder (ADHD) and drug dependence. The intron 6(G→T) variant was significantly associated with platelet serotonin levers. Only the association with TS was significant with a Bonferroni correction (p = 0.005). Our purpose here is not to claim these associations are proven, but rather to report preliminary results and show that easily testable polymorphisms are available. We hope to encourage additional research into the potential role the TDO2 gene in these and other psychiatric disorders.

Original languageEnglish
Pages (from-to)307-318
Number of pages12
JournalPharmacogenetics
Volume6
Issue number4
DOIs
StatePublished - 1996

ASJC Scopus Subject Areas

  • Genetics
  • General Pharmacology, Toxicology and Pharmaceutics

Keywords

  • Oxygenase
  • Polymorphism
  • Serotonin
  • Tryptophan
  • Tryptophan 2,3 dioxygenase

Cite this